Similarly, inhibitors of SCD1 (g-PPT) and FAS (orlistat) were found to impair lipid synthesis, thereby reducing LD levels in cancer cells, and enhancing the efficacy of combined drug treatments [82,88,89]. This evidence concerns the gene SCD and cancer.